Instil Bio Company

Instil Bio is a global, clinical-stage cell therapy company developing tumour-infiltrating lymphocytes (TIL) to treat solid tumour cancers. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and the first-in-human study of its next-generation engineered TIL. Their optimized TIL therapies leverage our platform for TIL manufacturing, which has been designed to improve TIL therapy's scalability, logistics, and accessibility. The company is also developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, CoStAR platform. Instil Bio has research and cell therapy manufacturing facilities and offices in Los Angeles and Dallas, USA and Manchester, UK.
Industry: Regenerative Medicine
Headquarters: Manchester, United Kingdom
Founded Date: 2018
Employees Number: 101-250
Funding Status: Early Stage Venture
Total Funding: £156 115 960
Last Funding Date: 08-03-2020
Last Funding Type: Series B

Visit Website
Register and Claim Ownership